Carrillo ER, Núñez MFN, Alvarado MC

Idioma: Español
Referencias bibliográficas: 40
Paginas: 28-35
Archivo PDF: 118.99 Kb.

RESUMEN

Objetivo. Evaluar la utilidad del azul de metileno en un paciente con choque séptico.
Diseño. Reporte de un caso y revisión de la literatura.
Sitio. Una UCI de un hospital de tercer nivel de México, D.F.
Paciente. Una mujer de 75 años de edad que ingresó a la UCI por choque refractario.
Intervenciones. Ventilación mecánica, administración de líquidos, dobutamina, norepinefrina, azul de metileno, antibióticos, monitoreo invasivo y no invasivo.
Mediciones y principales resultados. Se administró azul de metileno, 2 mg/kg por vía intravenosa durante 180 minutos y se midieron parámetros hemodinámicos basales a los 15, 30, 45, 60, 120 y 180 minutos. Se observó un incremento de la presión arterial media, índice cardiaco, resistencias vasculares, disponibilidad de oxígeno y función diastólica. Sin embargo, más tarde se observó un deterioro progresivo cardiovascular y la paciente falleció.
Conclusión. El azul de metileno mejora transitoriamente el estado hemodinámico de los pacientes con choque séptico.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Groeneveld ABJ, Bronsveld W, Thijs LG. Hemodynamic determinants of mortality in human septic shock. Surgery 1986;99:140-153.

2. Lowry SF. Sepsis and complications. Clinical definitions and therapeutic prospects. Crit Care Med 1994;22:S1-S2.

3. Beasley D. Interleukin 1 and endotoxin activate soluble guanylate cyclase in vascular smooth muscle. Am J Physiol 1990;259:R38-R44.

4. Joulou-Schaeffer G, Gray G, Fleming I. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990;259:H1038-H1043.

5. Brady AJB, Warren JB, Poole-Wilson PA et al. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993;265:H176-H182.

6. Meyer J, Lentz CW, Stothert JC et al. Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit Care Med 1994;22:306-312.

7. Petros A, Lamb G, Leone A et al. Effects of nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-39.

8. Lorente JA, Landin L, De Pablo R et al. L-arginine pathway in b sepsis syndrome. Crit Care Med 1993;21:1287-1295.

9. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992;26:48-57.

10. Evans T, Carpenter A, Kinderman H. Evidence of increase nitric oxide production in patients with the sepsis syndrome. Circ Shock 1993;41:77-81.

11. Lorence JA, Landin L, Renes E et al. Role of the nitric oxide in the hemodynamic changes in sepsis. Crit Care Med 1993;21:759-767.

12. Moncada S, Palmer RLJ, Higg EA. Nitric Oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991:43;109-142.

13. Karn PCA, Govender G. Nitric oxide. Basic science and clinical applications. Anaesthesia 1994;49:515-521.

14. Klabunde RE, Ritger RC. NG-monometyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun 1991;178:1135-1141.

15. Geroulanos S, Shilling J, Cakmakci M et al. Inhibition of NO synthesis in septic shock. Lancet 1992;339:434-435.

16. Isao Tsuneyoshi, Yuichi Kanmura, Nozumu Yoshimura. Nitric oxide as a mediator of reduced arterial responsiveness in septic patients. Crit Care Med 1996;24:1083-1086.

17. Balligand J-L, Ungureanu D, Kelly RA et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage conditioned medium. J Clin Invest 1993;91:2314-2319.

18. Hollenberg SM, Cunnion RE, Zimmenberg J. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to catecholamines in septic rats. Am J Physiol 1993;264 (Heart Circ Physiol (33):H660-H663.

19. Coob JP, Natanson C, Hoffman WD et al. N-amino-L-arginine, an inhibitor on nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 1992;176:1175-1182.

20. Gardines SM, Compton AM et al. Control of regional blood flow by endothelium derived nitric oxide. Hypertension 1990;15:486-492.

21. Hutcheson IR, Whittle BJR et al. Role of nitric oxide in maintening vascular integrity in endotoxin induced acute intestinal damage in the rat. Br J Pharmacol 1990;101:815-820.

22. Robertson FM, Offner PJ, Ciceri DP et al. Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch Surg 1994;129:149-156.

23. Hall HA, Kulig KW, Rumack BH. Drug and chemical-induced methaemoglobinemia:clinical features and management. Med Toxicol 1986;1:253-260.

24. Keaney JF Jr, Puyana J-C, Francis S et al. Methylene blue reverses endotoxin-induced hypotension. Circ Research 1994;74:121-125.

25. Martín W, Villani GM, Jothianandan D et al. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985;232:708-716.

26. Schneider F, Lutun Ph, Couchot A et al. Plasma cyclic guanosine 3'-5' monophosphate concentrations and low vascular resistances in human septic shock. Intensive Care Med 1993;19:99-104.

27. Okamura T, Yoshida K, Toda N. Supression by methylene blue of prostaglandin I2 synthesis in isolated dog renal arteries. J Pharmacol Exp Ther 1990;254:198-203.

28. Paya D, Gray GA, Stoclet JC. Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 1993;21:926-930.

29. Wolin SW, Cherry PD, Rodenburg JM et al. Methylene blue inhibits vasodilation of skeletal muscle arterioles to acetylcholine and nitric oxide via the extracellular generation of superoxide anion. J Pharmacol Exp Ther 1990;254:872-876.

30. Finker MS, Oddis CV, Jacob TD et al. Negative inotropic effect of cytokines on the heart mediated via the nitric oxide. Science 1992;257:387389.

31. Schneider F, Lutun PH, Masselmann M et al. Methylene blue increases systemic vascular resistances in human septic shock. Intensive Care Med 1992;18:309-311.

32. Preiser J-C, Lejeune P, Roman A et al. Methylene blue in septic shock: A clinical trial. Crit Car Med 1995;23:259-264.

33. Catharina RGH, Daemen-Gukbbles, Paul HP et al. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363-1369.

34. Gachot B, Bedos JP, Veber B et al. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995;21:1027-1031.

35. Zhang H, Rogiers P, Preiser JC et al. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med 1995;25:1711-1721

36. Samsel RW, Nelson DP, Sanders WM et al. Effects of endotoxin in systemic and skeletal muscle O2 extraction. J Appl Physiol 1988;65:13771382.

37. De Belder AJ, Radomski MW, Why HJF et al. Nitric oxide synthase activities in human myocardium. Lancet 1993;341:84-85.

38. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans Assessment by bicoronaty sodium nitroprusside infusion. Circulation 1994;89:2070-2078.

39. Mayer B, Brunner F, Schmidt K. Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 1993;45:367-374.

40. Shimizu S, Yamamoto T, Momose K. Inhibition by methylene blue of the L-arginine metabolism to L-citrulline coupled with nitric oxide synthesis in cultured endothelial cells. Res Commun chem Pathol Pharmacol 1993;82:35-48.